Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc

NEW
NAS:REGN (USA)   Ordinary Shares
$ 634.14 -26.86 (-4.06%) 04:00 PM EST
16.57
P/B:
2.37
Market Cap:
$ 69.33B
Enterprise V:
$ 65.96B
Volume:
848.59K
Avg Vol (2M):
948.64K
Warning! GuruFocus detected 3 Severe warning signs with REGN. Try a 7-Day Free Trial to check it out.
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
848.59K
Market Cap $:
69.33B
16.57
Avg Vol (2M):
948.64K
Enterprise Value $:
65.96B
PB Ratio:
2.37
Website SEC Filings Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Regeneron Pharmaceuticals Inc logo
Regeneron Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
ISIN : US75886F1075
https://www.regeneron.com
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Share Class Description:

REGN: Ordinary Shares
Compare
Compare
ALNYONCVRTXBNTXSMMTUTHRINSMRPRXINCYMRNAASX:CSLXKRX:207940XBRU:ARGXXBRU:UCBXKRX:068270XKRX:196170OCSE:GMABHKSE:02269BMRNSHSE:603392
Traded in other countries / regions
REGN.USA0R2M.UKREGN34.BrazilREGN.MexicoRGO.GermanyREGN.Austria1REGN.Italy
Index Membership
S&P 500NASDAQ 100Russell 1000Russell 3000
IPO Date
1991-04-02
Description
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Financial Strength

9/10
Name Current Vs Industry Vs History
Cash-To-Debt 3.33
Equity-to-Asset 0.78
Debt-to-Equity 0.09
Debt-to-EBITDA 0.51
Interest Coverage 74.13
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.6
Distress
Grey
Safe
Beneish M-Score -2.25
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

9/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -4.9
3-Year EBITDA Growth Rate -18.8
3-Year EPS without NRI Growth Rate -13
3-Year FCF Growth Rate -19.2
3-Year Book Growth Rate 15.7
Future 3-5Y EPS without NRI Growth Rate Estimate 6.76
Future 3-5Y Total Revenue Growth Rate Estimate 6

Momentum Rank

1/10
Name Current Vs Industry Vs History
5-Day RSI 35.63
9-Day RSI 39.38
14-Day RSI 41.93
3-1 Month Momentum % -0.17
6-1 Month Momentum % -31.81
12-1 Month Momentum % -26.26

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.73
Quick Ratio 3.95
Cash Ratio 2.28
Days Inventory 528.81
Days Sales Outstanding 148.68
Days Payable 115.82

Dividend & Buy Back

Name Current Vs Industry Vs History
Dividend Yield % 0.13
Forward Dividend Yield % 0.53
5-Year Yield-on-Cost % 0.13
3-Year Average Share Buyback Ratio -0.3
Shareholder Yield % 3.13

Profitability Rank

9/10
Name Current Vs Industry Vs History
Gross Margin % 86.13
Operating Margin % 28.81
Net Margin % 31.07
FCF Margin % 24.92
ROE % 15.78
ROA % 12.34
ROIC % 16.65
3-Year ROIIC % -47.41
ROC (Joel Greenblatt) % 49.29
ROCE % 15.05
Years of Profitability over Past 10-Year 10

GF Value Rank

8/10
Name Current Vs Industry Vs History
PE Ratio 16.57
Forward PE Ratio 14.89
PE Ratio without NRI 14.52
Shiller PE Ratio 20.06
Price-to-Owner-Earnings 26.16
PEG Ratio 1.5
PS Ratio 5.15
PB Ratio 2.37
Price-to-Tangible-Book 2.46
Price-to-Free-Cash-Flow 20.58
Price-to-Operating-Cash-Flow 16.5
EV-to-EBIT 13.64
EV-to-Forward-EBIT 13.64
EV-to-EBITDA 12.4
EV-to-Forward-EBITDA 12.21
EV-to-Revenue 4.64
EV-to-Forward-Revenue 4.53
EV-to-FCF 18.64
Price-to-GF-Value 0.73
Price-to-Projected-FCF 0.96
Price-to-DCF (Earnings Based) 0.46
Price-to-DCF (FCF Based) 0.66
Price-to-Median-PS-Value 0.67
Price-to-Peter-Lynch-Fair-Value 1.98
Price-to-Graham-Number 1.26
Price-to-Net-Current-Asset-Value 6.78
Price-to-Net-Cash 114.67
Earnings Yield (Greenblatt) % 7.33
FCF Yield % 5.1
Forward Rate of Return (Yacktman) % 12.35

Financials (Next Earnings Date:2025-05-02 Est.)

REGN's 30-Y Financials
AAPL
Income Statement Breakdown FY
Not Enough Data
AAPL
Balance Sheet Breakdown
Not Enough Data
AAPL
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:REGN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Regeneron Pharmaceuticals Inc Executives

Details

GF Value: $868.53

REGN

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 14,202
EPS (TTM) ($) 38.28
Beta 0.32
3-Year Sharpe Ratio 0.14
3-Year Sortino Ratio 0.21
Volatility % 32.56
14-Day RSI 41.93
14-Day ATR ($) 20.258571
20-Day SMA ($) 689.16
12-1 Month Momentum % -26.26
52-Week Range ($) 633.1 - 1211.1999
Shares Outstanding (Mil) 109.32

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Regeneron Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Regeneron Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Regeneron Pharmaceuticals Inc Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc(REGN)'s stock price today?
The current price of REGN is $634.14. The 52 week high of REGN is $1211.20 and 52 week low is $633.10.
When is next earnings date of Regeneron Pharmaceuticals Inc(REGN)?
The next earnings date of Regeneron Pharmaceuticals Inc(REGN) is 2025-05-02 Est..
Does Regeneron Pharmaceuticals Inc(REGN) pay dividends? If so, how much?
The  Dividend Yield %  of Regeneron Pharmaceuticals Inc(REGN) is 0.13% (As of Today), Highest Dividend Payout Ratio of Regeneron Pharmaceuticals Inc(REGN) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Regeneron Pharmaceuticals Inc(REGN) is 0.53%. For more information regarding to dividend, please check our Dividend Page.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.